Leronlimab downregulates PD-1 which is the receptor for PD-L1 which Keytruda targets. With the level leronlimab could downregulate PD-1, Keytruda would add little to no benefit to leronlimab's efficacy. Whether or not Merck is aware of this is whether or not they monitored PD-1 levels in the pre-clinical study.